companydata.dkcompanydata.dk

ROS Therapeutics Holding ApS: Financial statements 2022

CVR: 39507056

Source: annual report 2022, Danish Business Authority

01/01/2022 – 31/12/2022

ROS Therapeutics Holding ApS (CVR 39507056) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -12,500 and a net result of DKK -13,879 compared with DKK -4,284,829 the year before. Equity in the 2022 report amounted to DKK -229,117. The company had 1 employee in the financial year.

Gross Profit
DKK -12,500
Profit/Loss
DKK -13,879
Equity
DKK -229,117
Total Assets
DKK 34,689
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022--13K-14K-229K1
2021--13K-4.3M-225K1
2020--13K4M4.1M1
2019--15K-12K66K1

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on ROS Therapeutics Holding ApS

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

ROS Therapeutics Holding ApS: The 2021 annual report is outJun 26, 2022

ROS Therapeutics Holding ApS has published its annual report for 2021. Gross profit came to DKK -12,500, and the net result was DKK -4,284,829.

About ROS Therapeutics Holding ApS

ROS Therapeutics Holding ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Hanne Damgaard Jensen. The company is owned by SPORCON LIFESCIENCE ADVISORS ApS and HDJ & LEJ Invest ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -10,750 and a net result of DKK -26,512 compared with DKK -14,342 the year before. Equity in the 2025 report amounted to DKK -116,804.

Source: annual report 2025, Danish Business Authority

Other financial years